Collongues Nicolas, de Seze Jérôme
Department of Neurology, University Hospitals of Strasbourg, Strasbourg, France.
Department of Neurology, Hôpital de Hautepierre, 1 avenue Molière, 67098, Strasbourg Cedex, France.
Ther Adv Neurol Disord. 2016 May;9(3):180-8. doi: 10.1177/1756285616632653. Epub 2016 Mar 23.
Neuromyelitis optica spectrum disorders (NMOSDs) is a new concept which includes classical neuromyelitis optica (NMO) and partial forms of NMO such as recurrent optic neuritis with positive aquaporin-4 antibodies (AQP4) or brainstem symptoms (intractable hiccups or vomiting). This disease is clearly distinguished from multiple sclerosis (MS) and the therapeutic approach is clearly different. Rituximab is actually considered to be one of the most efficient treatments of NMOSD, even if class I studies are clearly lacking. In the present review, we describe the state of the art about rituximab treatment in NMOSD, including adults and children, plus its efficacy and tolerance and we also underline the questions that should be addressed in the near future.
视神经脊髓炎谱系障碍（NMOSDs）是一个新概念，它包括经典的视神经脊髓炎（NMO）以及NMO的部分形式，如伴有水通道蛋白4抗体（AQP4）阳性的复发性视神经炎或脑干症状（顽固性呃逆或呕吐）。这种疾病与多发性硬化症（MS）有明显区别，治疗方法也明显不同。利妥昔单抗实际上被认为是NMOSD最有效的治疗方法之一，即使目前明显缺乏I类研究。在本综述中，我们描述了利妥昔单抗治疗NMOSD（包括成人和儿童）的最新情况，及其疗效和耐受性，我们还强调了在不久的将来应该解决的问题。
